Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RX-3117 in advanced malignancies
NCT02030067Phase 2Completed
- Sponsor
- Processa Pharmaceuticals, Inc.
- Start
- Dec 2013
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roducitabine in solid tumor, pancreatic cancer (PC), bladder cancer, sponsored by Processa Pharmaceuticals, Inc.. Started Dec 2013; status: completed.
02
Drugs
roducitabine
03
Conditions
solid tumorpancreatic cancer (PC)bladder cancer
Beyond the preview
Go deeper on NCT02030067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02030067.